Myriad Genetics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 31.2 million compared to USD 42.3 million a year ago. Basic loss per share from continuing operations was USD 0.36 compared to USD 0.52 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.18 USD | +1.11% | -1.73% | -5.02% |
Mar. 20 | Myriad Genetics Gets US Patent for SneakPeek Snap Device | MT |
Feb. 27 | Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.02% | 1.64B | |
+0.89% | 12.8B | |
-10.29% | 7.61B | |
+1.78% | 5.41B | |
-1.16% | 4.51B | |
+5.74% | 4.49B | |
-50.70% | 3.3B | |
+12.21% | 2.73B | |
-16.13% | 2.02B | |
-11.50% | 1.73B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023